{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T02:37:58Z","timestamp":1783391878773,"version":"3.54.6"},"reference-count":42,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.vaccine.2024.07.046","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T20:04:03Z","timestamp":1721505843000},"page":"126145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit vaccine immunogenicity"],"prefix":"10.1016","volume":"42","author":[{"given":"Guo-Qing","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Ying","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0682-285X","authenticated-orcid":false,"given":"Xing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1966-251X","authenticated-orcid":false,"given":"Rui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3696-339X","authenticated-orcid":false,"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"579","key":"10.1016\/j.vaccine.2024.07.046_b0005","doi-asserted-by":"crossref","first-page":"eabd1525","DOI":"10.1126\/scitranslmed.abd1525","article-title":"Development and deployment of COVID-19 vaccines for those most vulnerable","volume":"13","author":"Koff","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.07.046_b0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/14760584.2021.1991794","article-title":"SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways","volume":"21","author":"Mekonnen","year":"2022","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2024.07.046_b0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2021.01.001","article-title":"Recombinant protein vaccines, a proven approach against coronavirus pandemics","volume":"170","author":"Pollet","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2024.07.046_b0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","article-title":"RBD-Fc-Based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response","volume":"5","author":"Liu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.vaccine.2024.07.046_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104574","article-title":"Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine","volume":"92","author":"Deliyannis","year":"2023","journal-title":"EBioMedicine"},{"issue":"13","key":"10.1016\/j.vaccine.2024.07.046_b0030","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.vaccine.2023.02.057","article-title":"A randomized phase I\/II safety and immunogenicity study of the montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452","volume":"41","author":"Feitsma","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.046_b0035","article-title":"Resolving adjuvant mode of action to enhance vaccine efficacy","volume":"77","author":"Zhou","year":"2022","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2024.07.046_b0040","doi-asserted-by":"crossref","first-page":"e0288486","DOI":"10.1371\/journal.pone.0288486","article-title":"CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2","volume":"18","author":"Laotee","year":"2023","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.vaccine.2024.07.046_b0045","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/vaccines11040713","article-title":"Screening of efficient adjuvants for the RBD-based subunit vaccine of SARS-CoV-2","volume":"11","author":"Shi","year":"2023","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2024.07.046_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9090957","article-title":"COVID-19 subunit vaccine with a combination of TLR1\/2 and TLR3 agonists induces robust and protective immunity","volume":"9","author":"Jeong","year":"2021","journal-title":"Vaccines"},{"issue":"7","key":"10.1016\/j.vaccine.2024.07.046_b0055","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/vaccines9070744","article-title":"Immunogenicity studies of plant-produced SARS-CoV-2 receptor binding domain-based subunit vaccine candidate with different adjuvant formulations","volume":"9","author":"Siriwattananon","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2024.07.046_b0060","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2015.03","article-title":"Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against middle east respiratory syndrome coronavirus","volume":"13","author":"Zhang","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.vaccine.2024.07.046_b0065","first-page":"1","article-title":"STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs","author":"Liu","year":"2022","journal-title":"Cell Res"},{"issue":"2","key":"10.1016\/j.vaccine.2024.07.046_b0070","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions","volume":"13","author":"Brennan","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2024.07.046_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqab013","article-title":"Harnessing NKT cells for vaccination","author":"Burn","year":"2021","journal-title":"Oxf Open Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2024.07.046_b0080","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2217\/imt.13.175","article-title":"Optimizing NKT cell ligands as vaccine adjuvants","volume":"6","author":"Carre\u00f1o","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.vaccine.2024.07.046_b0085","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1021\/acsinfecdis.2c00296","article-title":"A new iNKT-cell agonist-adjuvanted SARS-CoV-2 subunit vaccine elicits robust neutralizing antibody responses","volume":"8","author":"Li","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.vaccine.2024.07.046_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.carres.2022.108527","article-title":"iNKT cell agonists as vaccine adjuvants to combat infectious diseases","volume":"513","author":"Li","year":"2022","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.vaccine.2024.07.046_b0095","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3389\/fimmu.2017.00879","article-title":"Enhancement of adjuvant functions of natural killer T cells using nanovector delivery systems: application in anticancer immune therapy","volume":"8","author":"Ghinnagow","year":"2017","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2024.07.046_b0100","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijpharm.2017.07.054","article-title":"Solubilization of \u03b1-galactosylceramide in aqueous medium: impact on natural killer T cell activation and antitumor responses","volume":"530","author":"Macho-Fernandez","year":"2017","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.vaccine.2024.07.046_b0105","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3390\/pharmaceutics15071884","article-title":"Aluminum adjuvants\u2014\u2018Back to the Future\u2019","volume":"15","author":"Laera","year":"2016","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.vaccine.2024.07.046_b0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41541-018-0089-x","article-title":"Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want","volume":"3","author":"HogenEsch","year":"2018","journal-title":"NPJ Vaccines"},{"issue":"43","key":"10.1016\/j.vaccine.2024.07.046_b0115","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj3107","article-title":"Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants","volume":"7","author":"Zhang","year":"2021","journal-title":"Sci Adv"},{"issue":"44","key":"10.1016\/j.vaccine.2024.07.046_b0120","doi-asserted-by":"crossref","first-page":"7711","DOI":"10.1016\/j.vaccine.2011.07.136","article-title":"\u03b1-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice","volume":"29","author":"Li","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.046_b0125","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.2001283","article-title":"Glycolipid-containing nanoparticle vaccine engages invariant NKT cells to enhance humoral protection against systemic bacterial infection but abrogates T-independent vaccine responses","author":"Shute","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2024.07.046_b0130","first-page":"12","article-title":"Use of a clostridioides difficile murine immunization and challenge model to evaluate single and combination vaccine adjuvants consisting of alum and NKT cell-activating ligands","author":"Lang","year":"2022","journal-title":"Front Immunol"},{"issue":"263","key":"10.1016\/j.vaccine.2024.07.046_b0135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009980","article-title":"Rational design of small molecules as vaccine adjuvants","volume":"6","author":"Wu","year":"2014","journal-title":"Sci Transl Med"},{"issue":"40","key":"10.1016\/j.vaccine.2024.07.046_b0140","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2013.07.019","article-title":"Control of antigen-binding to aluminum adjuvants and the immune response with a novel phosphonate linker","volume":"31","author":"Lu","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.046_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101426","article-title":"The continued advance of vaccine adjuvants - \u201cWe Can Work It Out\u201d","volume":"50","author":"O\u2019Hagan","year":"2020","journal-title":"Semin Immunol"},{"issue":"629","key":"10.1016\/j.vaccine.2024.07.046_b0150","doi-asserted-by":"crossref","first-page":"eabj5305","DOI":"10.1126\/scitranslmed.abj5305","article-title":"An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice","volume":"14","author":"Nanishi","year":"2022","journal-title":"Sci Transl Med"},{"issue":"15","key":"10.1016\/j.vaccine.2024.07.046_b0155","doi-asserted-by":"crossref","first-page":"11554","DOI":"10.1021\/acs.jmedchem.1c00881","article-title":"Potent neutralizing antibodies elicited by RBD-Fc-based COVID-19 vaccine candidate adjuvanted by the Th2-skewing iNKT cell agonist","volume":"64","author":"Wang","year":"2021","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.vaccine.2024.07.046_b0160","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1021\/acsmedchemlett.3c00154","article-title":"Conformationally restricted analogues of \u03b1-galactosylceramide as adjuvant in COVID-19 subunit vaccine","volume":"14","author":"Hu","year":"2023","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"10.1016\/j.vaccine.2024.07.046_b0165","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1021\/ar050006z","article-title":"\u03b1-C-galactosylceramides: synthesis and immunology","volume":"39","author":"Franck","year":"2006","journal-title":"Acc Chem Res"},{"issue":"9","key":"10.1016\/j.vaccine.2024.07.046_b0170","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1073\/pnas.0407488102","article-title":"Modulation of CD1d-restricted NKT Cell responses by using N-Acyl variants of alpha-galactosylceramides","volume":"102","author":"Yu","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.vaccine.2024.07.046_b0175","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2024.07.046_b0180","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2024.07.046_b0185","first-page":"12","article-title":"Plant-produced receptor-binding domain of SARS-CoV-2 elicits potent neutralizing responses in mice and non-human primates","author":"Siriwattananon","year":"2021","journal-title":"Front Plant Sci"},{"issue":"12","key":"10.1016\/j.vaccine.2024.07.046_b0190","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1021\/acs.jmedchem.6b00489","article-title":"Incorporation of phosphonate into benzonaphthyridine toll-like receptor 7 agonists for adsorption to aluminum hydroxide","volume":"59","author":"Cortez","year":"2016","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.vaccine.2024.07.046_b0205","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1172\/JCI24762","article-title":"Glycolipid antigen induces long-term natural killer T cell anergy in mice","volume":"115","author":"Parekh","year":"2005","journal-title":"J Clin Invest"},{"issue":"25","key":"10.1016\/j.vaccine.2024.07.046_b0210","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1016\/j.vaccine.2009.01.047","article-title":"Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy","volume":"27","author":"Thapa","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2024.07.046_b0215","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2567.2008.02943.x","article-title":"Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells","volume":"127","author":"Li","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2024.07.046_b0220","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2016.11.011","article-title":"Adsorption of a synthetic TLR7\/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: a formulation approach","volume":"244","author":"Fox","year":"2016","journal-title":"J Controlled Release"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24008077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24008077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T11:16:28Z","timestamp":1724066188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24008077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":42,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0264410X24008077"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.07.046","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit vaccine immunogenicity","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.07.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126145"}}